Tag: antibody-drug conjugate

A new study published in NEJM and led by global principal investigator Aditya Bardia, MD, director of Translational Research Integration at the UCLA Health Jonsson Comprehensive Cancer Center, found trastuzumab deruxtecan (T-DXd), an antibody-drug conjugate, significantly improves progression-free survival compared to…